0001567619-21-018627.txt : 20211022 0001567619-21-018627.hdr.sgml : 20211022 20211022213635 ACCESSION NUMBER: 0001567619-21-018627 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211020 FILED AS OF DATE: 20211022 DATE AS OF CHANGE: 20211022 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Treace John T. CENTRAL INDEX KEY: 0001856380 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40355 FILM NUMBER: 211342004 MAIL ADDRESS: STREET 1: C/O TREACE MEDICAL CONCEPTS, INC. STREET 2: 203 FORT WADE ROAD, SUITE 150 CITY: PONTE VEDRA STATE: FL ZIP: 32081 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TREACE MEDICAL CONCEPTS, INC. CENTRAL INDEX KEY: 0001630627 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 471052611 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 FORT WADE ROAD STREET 2: SUITE 150 CITY: PONTE VEDRA STATE: FL ZIP: 32081 BUSINESS PHONE: (904) 373-5940 MAIL ADDRESS: STREET 1: 203 FORT WADE ROAD STREET 2: SUITE 150 CITY: PONTE VEDRA STATE: FL ZIP: 32081 4 1 doc1.xml FORM 4 X0306 4 2021-10-20 0 0001630627 TREACE MEDICAL CONCEPTS, INC. TMCI 0001856380 Treace John T. C/O TREACE MEDICAL CONCEPTS, INC. 203 FORT WADE ROAD, SUITE 150 PONTE VEDRA FL 32081 1 1 1 0 Chief Executive Officer Common Stock 2021-10-20 4 S 0 22612 24.7891 D 5894968 D Common Stock 2021-10-20 4 S 0 8215 25.3654 D 5886753 D Common Stock 2021-10-21 4 S 0 34325 19.8940 D 5852428 D Common Stock 2021-10-21 4 S 0 26701 20.6733 D 5825727 D Common Stock 2021-10-21 4 S 0 2768 21.4949 D 5822959 D Common Stock 2021-10-21 4 S 0 8207 23.0705 D 5814752 D Common Stock 2021-10-21 4 S 0 4044 23.8552 D 5810708 D Common Stock 2021-10-21 4 S 0 39 24.50 D 5810669 D Common Stock 2021-10-22 4 S 0 57534 20.7397 D 5753135 D Common Stock 2021-10-22 4 S 0 555 21.1578 D 5752580 D Common Stock 1605000 I By Wife Common Stock 1471250 I By Wife as cotrustee of the JTT Irrevocable Trust dated September 30, 2020 Common Stock 1839063 I As Trustee of the Tracy W. Treace Irrevocable Trust dated September 25, 2020 Common Stock 2021-09-07 4 A 0 408816 0 A 408816 I As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.21 to $25.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.22 to $25.69 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.21 to $20.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.22 to $21.16 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.98 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.37 to $23.36 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.38 to $24.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.12 to $21.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.14 to $21.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee. /s/ Lisa Taylor as Attorney-in-fact for John T. Treace 2021-10-22